SLC5A2 and chronic kidney disease: The observed change in proteinuria with SGLT2 inhibitors was much greater than that reported in DAPA-CKD and EMPA-KIDNEY (−35%, −41%, −45%, and −48% at 3, 6, 9, and 12 months).